Stock screenerAll disclosures →
EDGAR →
PRLD
Conviction 82HealthcareScan · Thu, Jun 25, 2026Three inside down
PRLD$4.10-4.10%
ResistanceSupportVol 14Insider buy22
Vol MA14 462.98K
Mar 26Apr 14May 1May 19Jun 8Jun 25
Price4.10
Change-4.10%
Gap+2.46%
Rel volume5.49×
Avg volume427.12K
Avg $ vol1.75M
SMA 204.07
SMA 504.38
SMA 2002.71
Price vs 50-6.40%
Price vs 200+51.13%
MA stackmixed
50/200 cross—
Supertrendup · 3.50
RSI (14)47
MACD hist0.02
MACD crossbull · 9d
Stoch %K / %D37 / 58
ADX (14)14
+DI / −DI21 / 19
RSI divergence—
MACD divergence—
ATR %+8.81%
ADR %7.95%
52w high5.52
52w low0.7799
From 52w high-25.82%
Above 52w low+425.07%
New 52w highNo
SqueezeOff
Bollinger width26.32%
%B0.52
Donchian pos53.88%
Donchian high4.69
Donchian low3.40
AVWAP (52w high)4.47
vs AVWAP high-8.33%
AVWAP (52w low)2.66
vs AVWAP low+53.84%
OBV trendDown
Chaikin MF (20)-0.20
Today vs 20d5.49×
Avg vol (14d)462.98K
Avg vol (20d)427.12K
Avg $ vol (20d)1.75M
Market cap326.15M
RS 3m (vs SPY)+24.60%
RS 6m (vs SPY)+91.80%
RS line new highNo
Trend template6/8
Technical rank69.0
1 week-5.86%
1 month+0.12%
3 months+25.61%
6 months+81.19%
1 year+367.41%
YTD+50.00%
P/E-3.28
P/B5.42
P/S26.87
P/FCF-5.79
EPS-1.29
Div yield—
ROE-165.33%
ROA-83.16%
Debt/Eq—
Current2.03
EV/EBITDA-2.96
Gross margin—
Net margin-819.59%
Rev growth73.43%
EPS growth21.76%
Price target—
Target upside—
Analyst rating—
Institutional—
Ent. value304.39M
Revenue4.58M
Net income-10.38M
Gross profit—
Free cash flow-56.37M
IndustryPHARMACEUTICAL PREPARATIONS
ExchangeNasdaq
Shares out79.65M
Employees79
ListedFri, Sep 25, 2020
Free float17.05M
Float %39.0%
Short interest1.69M
Days to cover5.4d
Short volume60.4%
Squeeze score73 / 100
Next earnings—
EPS forecast—
Last EPS vs est−$0.13 vs −$0.27
Last surprise+51.9% beat
Setup gradeA
Conviction82 / 100
Pattern quality—
Tech rank69.0 / 100
Group rank50 / 100
Status lane—
Setup direction—
Pattern family
Resistance—
Support—
Days since event—
Candle confirmThree inside down
News sentiment—
Financials as of Tue, Mar 31, 2026 · quarterly.
Congress activity
Disclosed STOCK Act trades in PRLD
No recent disclosed trades by Congress in PRLD. STOCK Act filings can lag the trade by up to 45 days.
Insider activity
SEC Form 4 transactions in PRLD · 10 buys
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Babler Martin Director · Director Stock Option (Right to Buy) · 2026-06-09 | Grant | 38K | $0 | 2026-06-09 | 2026-06-10 |
Baker Bros. Advisors (GP) LLC Director · Non-Qualified Stock Option (right to buy) · 2026-06-09 | Grant | 38K | $0 | 2026-06-09 | 2026-06-10 |
BAKER BROS. ADVISORS LP Director · Non-Qualified Stock Option (right to buy) · 2026-06-09 | Grant | 38K | $0 | 2026-06-09 | 2026-06-10 |
Sandor Victor Director · Director Stock Option (Right to Buy) · 2026-06-09 | Grant | 38K | $0 | 2026-06-09 | 2026-06-10 |
BAKER JULIAN Director · Non-Qualified Stock Option (right to buy) · 2026-06-09 | Grant | 38K | $0 | 2026-06-09 | 2026-06-10 |
Baker Brothers Life Sciences LP Director · Non-Qualified Stock Option (right to buy) · 2026-06-09 | Grant | 38K | $0 | 2026-06-09 | 2026-06-10 |
BAKER FELIX Director · Non-Qualified Stock Option (right to buy) · 2026-06-09 | Grant | 38K | $0 | 2026-06-09 | 2026-06-10 |
Dorton Katina Director · Director Stock Option (Right to Buy) · 2026-06-09 | Grant | 38K | $0 | 2026-06-09 | 2026-06-10 |
Bonita David P Director · Director Stock Option (Right to Buy) · 2026-06-09 | Grant | 38K | $0 | 2026-06-09 | 2026-06-10 |
FRIEDMAN PAUL A Director · Director Stock Option (Right to Buy) · 2026-06-09 | Grant | 38K | $0 | 2026-06-09 | 2026-06-10 |
SEC filings
EDGAR filings in PRLD · 1 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, cancel in one click.
Start free — 7-day full access →Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.